One of the emerging and mechanism based approaches for the treatment of type-II diabetes is dipeptidyl peptidase IV (DPP-IV; CD26; E.C. 3.4.14.5) inhibition with the help of small molecules [1–3]. This evidence concerns the gene DPP4 and type 2 diabetes mellitus.